"Does anyone think it is weird that PBT has recently got to $0.80 and AHZ hasn't??? The market isn't pricing AHZ's prospects correctly."
Of course there is always a HUGE risk with any drug in clinical development where as AHZ already has a revenue stream PBT does not. However if PBT successfully delivers here on the clinical trials currently underway it will likely have one of the biggest revenue streams of any drugs currently in market and certainly take Australia's hierarchy the only other possible competitor there is NEU's target market but again always uncertainty until drugs cross the line.
FWIW PBT also has an extremely tight Registry in comparison to AHZ so liquidity is scarce and price moves relatively easily.
AHZ - Top 20 - 36% - #1 Shareholder 17%
PBT - Top 20 - 80% - #1 Shareholder 56%
AHZ Price at posting:
14.5¢ Sentiment: None Disclosure: Held
